Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55

Key Points

• Analysts have a consensus “Hold” rating on Arvinas, with five buys, three holds, and two sells. The average 12-month price target is $14.55.
• ARVN opened at $7.45, below its 50-day and 200-day moving averages, with a market capitalization of approximately $480.7 million and a one-year trading range of $6.97 to $14.51.
• Arvinas significantly exceeded quarterly expectations, reporting $2.58 in earnings per share versus a projected loss of $0.37 and $249.7 million in revenue, up 1,014.7% year over year. Institutional investors own approximately 95.2% of the company’s stock.

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been assigned an average rating of "Hold" from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.55.

A number of equities analysts have issued reports on ARVN shares. Morgan Stanley set a $10.00 price objective on shares of Arvinas in a research report on Monday, August 10th. Wall Street Zen raised Arvinas from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $11.00 price objective (down from $15.00) on shares of Arvinas in a research report on Tuesday, August 4th. BTIG Research restated a "buy" rating and set a $18.00 target price on shares of Arvinas in a report on Tuesday, August 4th. Finally, Citigroup cut their price target on shares of Arvinas from $24.00 to $21.00 and set a "buy" rating on the stock in a report on Monday, August 10th.

Arvinas Price Performance

ARVN stock opened at $7.45 on Thursday. The firm has a 50 day simple moving average of $8.59 and a two-hundred day simple moving average of $8.96. The stock has a market cap of $480.67 million, a PE ratio of 74.51 and a beta of 1.80. Arvinas has a one year low of $6.97 and a one year high of $14.51.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $2.95. The business had revenue of $249.70 million for the quarter, compared to the consensus estimate of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The company's revenue for the quarter was up 1014.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.84) earnings per share. On average, research analysts expect that Arvinas will post 0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Engineers Gate Manager LP purchased a new stake in Arvinas in the second quarter worth $601,000. Integrated Wealth Concepts LLC purchased a new position in Arvinas during the second quarter valued at $48,000. Squarepoint Ops LLC lifted its position in Arvinas by 760.3% during the second quarter. Squarepoint Ops LLC now owns 201,822 shares of the company's stock valued at $1,677,000 after buying an additional 178,362 shares during the period. Corient Private Wealth LP boosted its holdings in shares of Arvinas by 15.9% during the 2nd quarter. Corient Private Wealth LP now owns 11,945 shares of the company's stock valued at $99,000 after buying an additional 1,637 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Arvinas during the 2nd quarter valued at $310,000. Institutional investors own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary PROTAC targeted protein degradation platform to design small-molecule therapies intended to direct unwanted proteins to the cell's natural disposal system.

Arvinas' programs have primarily focused on oncology. Its lead investigational program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.